Enzo Biochem Announces New York State Health Department Approval of New Women’s Health Diagnostics
June 08 2017 - 4:00PM
Business Wire
Underscores Enzo’s Growing Test Menu of High
Performing Molecular Diagnostics
Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York
State Department of Health has granted conditional approval for
three additional women’s health related molecular diagnostic tests
for use with the Company’s versatile and economic AmpiProbe®
platform. Approval was given for a real-time PCR-based method for
qualitative detection of Neisseria gonorrhoeae, Chlamydia
trachomatis and Trichomonas vaginalis in vaginal swab
specimens.
Elazar Rabbani, Ph.D., Enzo CEO and Chairman, commented “The
approval of these diagnostic tests adds to the Company’s growing
panel of women’s health diagnostics. Additionally, gonorrhoeae,
though one with the highest incidence among women’s sexually
transmitted diseases, tends also to be broadly prevalent among
men.
“Since the inception of Enzo, we have been committed to
advancing healthcare and in today’s challenging environment,
providing affordable, reliable diagnostic testing is an imperative.
These tests are part of a continued flow of robust products and
services to be released. The Company’s AmpiProbe®-based pipeline
includes an extensive line of assays for identification of
additional women’s health infectious diseases as well as for the
quantification of viral load in serum or plasma specimens. This
proprietary technology platform is the foundation for this ever
increasing line of medically relevant, cost-effective and easily
adaptable solutions for clinical laboratories. The Company’s unique
integrated Life Science-Clinical Lab structure is especially
instrumental in its ability to seamlessly develop and advance
products from innovation through validation and commercialization,”
he added.
In addition to these products, Enzo’s development program
includes a line of assays based on its proprietary flow cytometry
platform for such diverse applications as cancer, infectious
disease and immunology, to name a few. The Company also is
developing a line of products designed to aid pathologists in
differentiating the characteristics of various tumors from biopsy
specimens. Enzo molecular-based products are targeted at a market
currently estimated to be in excess of $3 billion worth of
laboratory service revenue domestically.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigations, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2016. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170608006284/en/
Enzo Biochem, Inc.Steve Anreder,
212-532-3232steven.anreder@anreder.comorCEOcast, Inc.Michael Wachs,
212-732-4300mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024